MX2021002668A - Plataforma de virus oncolitico para tratar el cancer hematologico. - Google Patents
Plataforma de virus oncolitico para tratar el cancer hematologico.Info
- Publication number
- MX2021002668A MX2021002668A MX2021002668A MX2021002668A MX2021002668A MX 2021002668 A MX2021002668 A MX 2021002668A MX 2021002668 A MX2021002668 A MX 2021002668A MX 2021002668 A MX2021002668 A MX 2021002668A MX 2021002668 A MX2021002668 A MX 2021002668A
- Authority
- MX
- Mexico
- Prior art keywords
- hematological cancer
- oncolytic virus
- treat hematological
- virus platform
- platform
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 230000002489 hematologic effect Effects 0.000 title abstract 3
- 244000309459 oncolytic virus Species 0.000 title 1
- 241000700562 Myxoma virus Species 0.000 abstract 2
- 108700019146 Transgenes Proteins 0.000 abstract 2
- 230000002519 immonomodulatory effect Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 210000000265 leukocyte Anatomy 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4725—Proteoglycans, e.g. aggreccan
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La divulgación proporciona un virus del Mixoma que expresa uno o más transgenes inmunomoduladores y su uso para inhibir y/o tratar un cáncer hematológico en un sujeto. La divulgación también proporciona un leucocito que tiene un virus del Mixoma que expresa uno o más transgenes inmunomoduladores y el uso del leucocito para la inhibición y/o tratamiento de un cáncer hematológico en un sujeto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862727307P | 2018-09-05 | 2018-09-05 | |
PCT/US2019/049598 WO2020051248A1 (en) | 2018-09-05 | 2019-09-04 | Oncolytic virus platform to treat hematological cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021002668A true MX2021002668A (es) | 2021-05-12 |
Family
ID=69722027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021002668A MX2021002668A (es) | 2018-09-05 | 2019-09-04 | Plataforma de virus oncolitico para tratar el cancer hematologico. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210252086A1 (es) |
EP (1) | EP3846829A4 (es) |
JP (1) | JP2022524173A (es) |
KR (1) | KR20210055740A (es) |
CN (1) | CN112969468A (es) |
AU (1) | AU2019336180A1 (es) |
CA (1) | CA3112788A1 (es) |
IL (1) | IL281252A (es) |
MX (1) | MX2021002668A (es) |
SG (1) | SG11202102272UA (es) |
TW (1) | TW202023582A (es) |
WO (1) | WO2020051248A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020198690A1 (en) * | 2019-03-28 | 2020-10-01 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Oncolytic myxoma virus expressing fast p14 to treat hematological cancer |
JP2022546539A (ja) | 2019-09-02 | 2022-11-04 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ | 粘液腫ウイルスを用いて癌を治療するための新しい腫瘍崩壊ウイルスプラットフォーム |
CA3157357A1 (en) * | 2019-10-10 | 2021-04-15 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic viruses that express multi-specific immune cell engagers |
WO2023192955A2 (en) * | 2022-03-30 | 2023-10-05 | Arizona Board Of Regents On Behalf Of Arizona State University | Cancer therapies comprising a nuclear export inhibitor and an oncolytic virus |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ541951A (en) * | 2003-03-07 | 2008-03-28 | Robarts Res Inst | Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection |
CN101137748B (zh) * | 2005-03-07 | 2011-12-14 | 罗巴斯研究机构 | 粘液瘤病毒与雷帕霉素的组合在治疗性处理中的应用 |
US9889197B2 (en) * | 2005-04-15 | 2018-02-13 | Macrogenics, Inc. | Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin |
AU2007256754B2 (en) * | 2006-06-01 | 2012-11-29 | Robarts Research Institute | Myxoma virus mutants for cancer treatment |
FR2946536B1 (fr) * | 2009-06-11 | 2011-07-29 | Agronomique Inst Nat Rech | Utilisation d'une souche attenuee de myxoma virus comme oncolytique |
WO2014089354A1 (en) * | 2012-12-07 | 2014-06-12 | The Regents Of The University Of California | Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
AU2014244286B2 (en) * | 2013-03-14 | 2018-11-08 | Duke University | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
ES2897782T3 (es) * | 2014-09-17 | 2022-03-02 | Merck Patent Gmbh | Método de tratamiento de las enfermedades de la metástasis ósea, medicamentos para el tratamiento y método para predecir el resultado clínico del tratamiento de las enfermedades causadas por metástasis ósea |
US20180021378A1 (en) * | 2014-12-31 | 2018-01-25 | Anthrogenesis Corporation | Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells |
WO2017210058A1 (en) * | 2016-06-01 | 2017-12-07 | Ibc Pharmaceuticals, Inc. | Combination therapy with t-cell redirecting bispecific antibodies and checkpoint inhibitors |
TW201825674A (zh) * | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現雙特異性接合分子的溶瘤病毒 |
US11459394B2 (en) * | 2017-02-24 | 2022-10-04 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
EP3585425A4 (en) * | 2017-02-27 | 2020-10-28 | Shattuck Labs, Inc. | PROCESSES FOR THE MANUFACTURE AND USE OF CHEMERICAL PROTEINS BASED ON EXTRACELLULAR DOMAIN |
CN107164338A (zh) * | 2017-06-27 | 2017-09-15 | 镇江市卫克生物科技有限公司 | 一种重组溶瘤病毒及其应用 |
JP2022546539A (ja) * | 2019-09-02 | 2022-11-04 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ | 粘液腫ウイルスを用いて癌を治療するための新しい腫瘍崩壊ウイルスプラットフォーム |
-
2019
- 2019-09-04 MX MX2021002668A patent/MX2021002668A/es unknown
- 2019-09-04 CA CA3112788A patent/CA3112788A1/en active Pending
- 2019-09-04 SG SG11202102272UA patent/SG11202102272UA/en unknown
- 2019-09-04 CN CN201980073063.0A patent/CN112969468A/zh active Pending
- 2019-09-04 AU AU2019336180A patent/AU2019336180A1/en active Pending
- 2019-09-04 KR KR1020217010051A patent/KR20210055740A/ko active Search and Examination
- 2019-09-04 EP EP19858456.7A patent/EP3846829A4/en active Pending
- 2019-09-04 WO PCT/US2019/049598 patent/WO2020051248A1/en unknown
- 2019-09-04 US US17/274,051 patent/US20210252086A1/en active Pending
- 2019-09-04 JP JP2021512408A patent/JP2022524173A/ja active Pending
- 2019-09-05 TW TW108132137A patent/TW202023582A/zh unknown
-
2021
- 2021-03-04 IL IL281252A patent/IL281252A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3846829A4 (en) | 2022-09-14 |
JP2022524173A (ja) | 2022-04-28 |
CN112969468A (zh) | 2021-06-15 |
CA3112788A1 (en) | 2020-03-12 |
IL281252A (en) | 2021-04-29 |
KR20210055740A (ko) | 2021-05-17 |
SG11202102272UA (en) | 2021-04-29 |
AU2019336180A1 (en) | 2021-04-15 |
TW202023582A (zh) | 2020-07-01 |
EP3846829A1 (en) | 2021-07-14 |
US20210252086A1 (en) | 2021-08-19 |
WO2020051248A1 (en) | 2020-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021002668A (es) | Plataforma de virus oncolitico para tratar el cancer hematologico. | |
CL2018000853A1 (es) | Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control inmunitarios para tratar el cáncer. | |
MX2022007472A (es) | Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario. | |
PH12018500869A1 (en) | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment | |
JOP20180008A1 (ar) | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b | |
WO2017096309A8 (en) | Methods of treatment of malignancies | |
EP3402500A4 (en) | COMBINATION THERAPY OF ONCOLYTIC VIRUS AND CHECKPOINT INHIBITOR | |
MX2021010528A (es) | Metodos y composiciones para el tratamiento de las ulceras. | |
EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
MA39717A (fr) | Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs | |
EP4286009A3 (en) | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy | |
EP3454911A4 (en) | ONCOLYTIC VIRUSES COMPRISING A GENE ESRAGE AND METHODS OF TREATING CANCER | |
EP4252851A3 (en) | Ezh2 inhibitors for treating lymphoma | |
MX2019005402A (es) | Terapias de combinacion del inhibidor de arginasa. | |
WO2017139570A8 (en) | Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccine | |
MX2020013808A (es) | Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer. | |
MX2019014059A (es) | Adenovirus antiangiogenico. | |
EP3876965A4 (en) | MULTI-THERAPIES BASED ON MICRO-ORGANISMS AND IMMUNE MODULATORS FOR USE IN THE TREATMENT OF CANCER | |
MX2017006015A (es) | Composiciones para usar en el tratamiento de cancer renal. | |
PH12019500927A1 (en) | Farnesyltransferase inhibitors for use in methods of treating cancer | |
MA51630A (fr) | Utilisation de virus oncolytiques, seuls ou en combinaison avec un inhibiteur de point de contrôle immunitaire, pour le traitement du cancer | |
MX2018010709A (es) | Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control. | |
IL281730A (en) | Combinations of the virus and axinia oncolytic and checkpoint suppressors of the immune system for the treatment of cancer, and pharmaceutical preparations containing these combinations | |
MX2021011871A (es) | Uso de virus oncoliticos en la terapia neoadyuvante del cancer. | |
MX2020013103A (es) | Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia. |